Roche Holding said the European Medicines Agency recommended extended approval of Actemra, an anti-interleukin-6 receptor antibody, for use in combination with standard treatment methotrexate in patients with rheumatoid arthritis. The company received the recommendation after providing the EU agency with two years of clinical data.

Full Story:

Related Summaries